Academic Journal
Predictors of Disease Activity After Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration Using Real-World Data from the PROOF Study
| العنوان: | Predictors of Disease Activity After Anti-VEGF Treatment for Neovascular Age-Related Macular Degeneration Using Real-World Data from the PROOF Study |
|---|---|
| المؤلفون: | Min Sagong, Jae Hui Kim, Se Joon Woo, Yu Cheol Kim, Heeyoon Cho, Young Hoon Lee, Iksoo Byon, Young Joon Jo, Hee Seung Chin, Jeonghee Kim, Jae Eun Chae, Se Woong Kang |
| المصدر: | Ophthalmology and Therapy, Vol 13, Iss 11, Pp 2839-2853 (2024) |
| بيانات النشر: | Adis, Springer Healthcare, 2024. |
| سنة النشر: | 2024 |
| المجموعة: | LCC:Ophthalmology |
| مصطلحات موضوعية: | Aflibercept, Age-related macular degeneration, Anti-vascular endothelial growth factor, Best-corrected visual acuity, Bevacizumab, Ranibizumab, Ophthalmology, RE1-994 |
| الوصف: | Abstract Introduction The aim of this study was to investigate the predictive factors for persistent disease activity following anti-vascular endothelial growth factors (anti-VEGF) and their long-term effects in patients to be treated for neovascular age-related macular degeneration (nAMD) under real-world conditions. Methods Retrospective data analysis of the PROOF study, a multi-center real-world retrospective chart review conducted across Korea in patients with nAMD included treatment-naive patients with nAMD who received first anti-VEGF (ranibizumab, bevacizumab, or aflibercept) between January 2017 and March 2019 was performed. All 600 patients (cohort 1) had a minimum follow-up of 12 months of which 453 patients (cohort 2) were followed-up for 24 months from baseline. Results At month 12 after anti-VEGF therapy, 58.10% (95% confidence interval [CI]: 54.09, 62.12) of patients and at month 24, 66.02% of patients continued to have persistent retinal fluid. At both months 12 and 24, predictive factors for persistent disease activity were fibrovascular pigment epithelial detachments (PED) (P = 0.0494) and retinal fluid at month 3 after loading phase (P = 0.0082). The mean changes in visual acuity were + 6.2, + 10.1, and + 13.3 letters and in the central subfield thickness were − 79.1 µm, − 96.3 µm, and − 134.4 µm at 12 months from baseline, in the bevacizumab, aflibercept, and ranibizumab groups, respectively. Conclusions The presence of retinal fluid after loading phase and fibrovascular PED were predictors of persistent disease activity after at least 1 year of anti-VEGF treatment. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 2193-8245 2193-6528 |
| Relation: | https://doaj.org/toc/2193-8245; https://doaj.org/toc/2193-6528 |
| DOI: | 10.1007/s40123-024-01021-x |
| URL الوصول: | https://doaj.org/article/e093050f9dca418a8cfe61554fecf86a |
| رقم الانضمام: | edsdoj.093050f9dca418a8cfe61554fecf86a |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 21938245 21936528 |
|---|---|
| DOI: | 10.1007/s40123-024-01021-x |